1. Abdul-Ghani, M. A., & DeFronzo, R. A. (2009). Pathophysiology of prediabetes. Current Diabetes Reports, 9, 193–199.
2. Abu-Taha, M., Rius, C., Hermenegildo, C., Noguera, I., Cerda-Nicolas, J. M., Issekutz, A. C., Jose, P. J., Cortijo, J., Morcillo, E. J., & Sanz, M. J. (2009). Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. Journal of Immunology, 183, 1393–1402.
3. Alberti, K. G., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Medicine: A Journal of the British Diabetic Association, 23, 469–480.
4. Andersson, B., Mattsson, L. A., Hahn, L., Marin, P., Lapidus, L., Holm, G., Bengtsson, B. A., & Bjorntorp, P. (1997). Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism, 82, 638–643.
5. Arias-Pulido, H., Royce, M., Gong, Y., Joste, N., Lomo, L., Lee, S. J., Chaher, N., Verschraegen, C., Lara, J., Prossnitz, E. R., & Cristofanilli, M. (2010). GPR30 and estrogen receptor expression: New insights into hormone dependence of inflammatory breast cancer. Breast Cancer Research and Treatment, 123, 51–58.